Corrigendum
A previous version of this report was published in July 2013. The report was corrected on page v in November 2013. For further information, or for copies of the original material, please contact Nihredit@soton.ac.uk.

Summary of changes

Page v

Original
The mixed-treatment comparison demonstrated that, in patients with non-squamous disease, pemetrexed (Alimta®, Eli Lilly and Company; PEM) + platinum (PLAT) increases OS statistically significantly compared with gemcitabine (Gemzar®, Eli Lilly and Company; GEM) + PLAT [hazard ratio (HR) = 0.85; 95% confidence interval (CI) 0.74 to 0.98] and that paclitaxel (Abraxane®, Celgene Corporation; PAX) + PLAT increases OS statistically significantly compared with docetaxel (Taxotere®, Sanofi-aventis; DOC) + PLAT (HR = 0.79, 95% CI 0.66 to 0.93).

Correction
The mixed-treatment comparison demonstrated that, in patients with non-squamous disease, pemetrexed (Alimta®, Eli Lilly and Company; PEM) + platinum (PLAT) increases OS statistically significantly compared with gemcitabine (Gemzar®, Eli Lilly and Company; GEM) + PLAT [hazard ratio (HR) = 0.85; 95% confidence interval (CI) 0.74 to 0.98] and that docetaxel (Taxotere®, Sanofi-aventis; DOC) + PLAT increases OS statistically significantly compared with paclitaxel (Abraxane®, Celgene Corporation; PAX) + PLAT (HR = 0.79, 95% CI 0.66 to 0.93).

Reference